Patent Board Rejects Challenge To Hair-Loss Drug Patent

Concert Pharmaceuticals Inc. secured a win Wednesday when an administrative patent tribunal validated a hair-loss treatment patent challenged by a rival drug company.

Incyte Corp. alleged Concert’s US Patent No. 10,561,659—for a formula intended to improve the body’s uptake of alopecia areata treatment in certain patients—didn’t cover a new idea. The Patent Trial and Appeal Board ruled, however, that the patent’s claims weren’t obvious from several prior inventions, allowing the full patent to stand.

In a Thursday statement, Concert said the outcome affirms the company’s plans to continue third-phase clinical trials on the enzyme inhibitor CTP-543 and to submit ...